Immunovant, Inc. (IMVT) |
|
41.985 2.025 (5.07%)
|
09-27 11:22 |
|
Open: |
42.5 |
Pre. Close: |
39.96 |
|
High:
|
44.19 |
Low:
|
41.35 |
|
Volume:
|
5,991,234 |
Market Cap:
|
5,486(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:47:36 AM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 51.61 One year: 60.28 |
| Support: |
Support1: 28.93 Support2: 19.5 |
| Resistance: |
Resistance1: 44.18 Resistance2: 51.61 |
| Pivot: |
24.31 |
| Moving Average: |
MA(5): 28.88 MA(20): 23.97
MA(100): 21.4 MA(250): 17.54 |
| MACD: |
MACD(12,26): 2.6 Signal(9): 0.7 |
| Stochastic oscillator: |
%K(14,3): 67.8 %D(3): 41.9 |
| RSI: |
RSI(14): 86.3 |
| 52-week: |
High: 44.18 Low: 4.61 |
| Average Vol(K): |
3-Month: 1,750 (K) 10-Days: 4,891 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMVT ] has closed above the upper band by 17.9%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 479.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
41.78 - 42.01 |
42.01 - 42.23 |
|
Low:
|
31.64 - 31.88 |
31.88 - 32.11 |
|
Close:
|
39.53 - 39.96 |
39.96 - 40.35 |
|
Company Description |
|
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. |
Headline News |
Wed, 27 Sep 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data - Nasdaq
Wed, 27 Sep 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data - Zacks Investment Research
Wed, 27 Sep 2023
Immunovant Inc (IMVT) is up 1.10% Wednesday In Premarket Trading - InvestorsObserver
Wed, 27 Sep 2023
IMVT Crosses Above Average Analyst Target - Nasdaq
Wed, 27 Sep 2023
Immunovant: Immune Boost, From Clinical Trials To Aggressive Bullish Stock (NASDAQ:IMVT) - Seeking Alpha
Tue, 26 Sep 2023
Immunovant announces proposed offering of $300M of common stock (NASDAQ:IMVT) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
131 (M) |
| Shares Float |
56 (M) |
|
% Held by Insiders
|
57.4 (%) |
|
% Held by Institutions
|
45.4 (%) |
|
Shares Short
|
4,900 (K) |
|
Shares Short P.Month
|
3,710 (K) |
Stock Financials |
|
EPS
|
-1.91 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.29 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-36.1 |
|
Return on Equity (ttm)
|
-66.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.79 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-170 (M) |
|
Levered Free Cash Flow
|
-71 (M) |
Stock Valuations |
|
PE Ratio
|
-22.28 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
18.5 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-32.76 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
